We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Could Revolutionize Cancer Diagnosis

By LabMedica International staff writers
Posted on 21 Sep 2016
Print article
Image: A colorized scanning electron micrograph (SEM) of esophageal cancer cells (Photo courtesy of the University of California-Davis).
Image: A colorized scanning electron micrograph (SEM) of esophageal cancer cells (Photo courtesy of the University of California-Davis).
A new blood test has been developed that could detect cancer earlier than ever before and it will change the way cancer is diagnosed, and in turn potentially save millions of lives.

The assay is based on a simple blood test and it could be used to identify cancer in undiagnosed patients. It would be used to screen people who are at-risk or are asymptomatic, meaning it could detect cancer even before symptoms begin to show.

Scientists at Swansea University Medical School (UK) have optimized this test over the past four years in more than 300 individuals using esophageal cancer as an example. The studies included healthy controls, pre-cancer patients and patients with cancer. The blood is stained with antibodies, which work as markers to see if there have been changes to the surface. It takes around 30 minutes to test the blood, and they estimate each test costs around GBP 35 or USD 46. The test was able to distinguish healthy volunteers and patients with a pre-cancerous condition of the esophagus, from those with cancer itself.

In healthy control individuals, only a few mutated cells are detected per million red blood cells with a mean of about five per million, but in cancer patients this can rise by over 10-fold to 50-100 mutants per million. In patients undergoing chemotherapy, who are exposed to drugs that deliberately induce DNA mutations, the levels can be several hundred per million. Interestingly, these red blood cell mutations do not play a direct role in the cancer development process. They are “collateral damage” produced in circulating blood cells as a by-product of a cancer developing internally. The benefit of the blood cell mutation is that it can be monitored in a simple, efficient, and non-invasive way. The actual test on the blood takes a few hours to perform in the laboratory and can be done in any standard pathology department, as it utilizes standard laboratory equipment.

Gareth Jenkins, PhD, a professor and lead investigator, said, “The test detects changes, known as mutations, in red blood cell surface proteins. These sugary proteins act as “Velcro” to stick cell recognition proteins to the cell surface. In mutated cells, the “Velcro” is missing and so the cells are “naked” for the protein of interest. Staining cells with fluorescent antibodies for the cell recognition proteins identifies normal from mutated cells which allows a mutant cell frequency to be calculated per person.” The study was presented on September 6, 2016, at the British Science Festival held at Swansea University, UK.

Related Links:
Swansea University Medical School

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.